← Back to Search

Behavioral Intervention

Neurofeedback for Depression

N/A
Recruiting
Led By Kymberly Young, PhD
Research Sponsored by Kymberly Young
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline vs up to one year

Summary

This trial tests if training brain activity can reduce symptoms of depression without medication.

Who is the study for?
This trial is for adults aged 18-55 with Major Depressive Disorder (MDD) who are either not on medication or have been stable on antidepressants for at least 4 weeks. Participants must be able to consent and complete questionnaires in English. Those with unstable health conditions, pregnant or breastfeeding women, individuals taking certain medications like antipsychotics or stimulants, and those with severe substance use disorders cannot join.
What is being tested?
The study tests if a type of brain scan feedback called rtfMRI-nf can help people by increasing the amygdala's response to positive memories as a treatment for depression. Participants will receive either actual neurofeedback or sham (fake) feedback as part of the study.
What are the potential side effects?
Since this trial involves non-invasive brain scans and feedback sessions without drugs, side effects may include discomfort from lying still during MRI scans, temporary headaches, dizziness after scanning sessions, and potential emotional distress.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline vs up to one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline vs up to one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Beck Depression Inventory (BDI-II)
Secondary study objectives
Life Functioning Questionnaire (LFQ)
Other study objectives
Autobiographical Memory Test

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Amygdala real-time fMRI neurofeedbackExperimental Treatment1 Intervention
Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
Group II: Sham feedbackPlacebo Group1 Intervention
Yoked sham - participants will see the amygdala activity of another subject who completed the intervention. Two sessions will be performed one week apart.

Find a Location

Who is running the clinical trial?

Kymberly YoungLead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled
University of PittsburghLead Sponsor
1,789 Previous Clinical Trials
16,359,423 Total Patients Enrolled
122 Trials studying Depression
34,269 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,918 Previous Clinical Trials
2,739,716 Total Patients Enrolled
701 Trials studying Depression
260,913 Patients Enrolled for Depression

Media Library

Amygdala real-time fMRI neurofeedback (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05703256 — N/A
Depression Research Study Groups: Amygdala real-time fMRI neurofeedback, Sham feedback
Depression Clinical Trial 2023: Amygdala real-time fMRI neurofeedback Highlights & Side Effects. Trial Name: NCT05703256 — N/A
Amygdala real-time fMRI neurofeedback (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05703256 — N/A
~126 spots leftby Apr 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top